Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, antisense to NCMAP" (ENSG00000298126) is a long non-coding RNA transcribed from the strand opposite to the protein-coding *NCMAP* gene. As a natural antisense transcript, it is believed to influence the expression, splicing, or stability of the sense (*NCMAP*) mRNA through mechanisms such as transcriptional interference, RNA masking, or formation of double-stranded RNA, potentially affecting gene regulation at the transcriptional or post-transcriptional level. While natural antisense transcripts as a class are increasingly recognized as regulators of gene expression and may play roles in disease through epigenetic silencing or promotion of specific isoforms, there is currently no evidence that this specific NAT is itself a receptor, enzyme, transporter, or direct therapeutic target, nor is there evidence for drug interactions or use as a biomarker[1][2][3][4].
Transcriptional interference; RNA masking; Double-stranded RNA-mediated silencing (RNA interference, siRNA formation); Chromatin remodeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to NCMAP (ENSG00000298126).